Overall, this phase 1b trial demonstrates that combined cagrilintide and semaglutide therapy is safe, well-tolerated, and offers clinically meaningful weight loss compared to placebo, warranting further investigation for weight management in obesity
Tendon and ligament repair, gastrointestinal mucosal healing, soft tissue recovery, and neuroprotective signaling are all supported by reproducible rodent and in vitro work, while the human evidence remains limited to one unpublished Phase 2 IBD trial and a small number of preliminary studies
Reported Effects Persistent celiac symptoms: In a Phase 2b trial of 342 adults on a gluten-free diet 12 months, 0.5 mg three times daily significantly reduced average weekly symptom scores versus placebo (p=0.022) the programs high-water mark [3]
The basic science is intriguing, Frank says